Jim Cramer Reveals AbbVie’s (ABBV) “Good Stuff”

We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. AbbVie Inc. (NYSE:ABBV) is one of the stocks discussed by Jim Cramer.

Pharmaceutical firm AbbVie Inc. (NYSE:ABBV)’s shares are up by 11% over the past year and are down by 9% year-to-date. Evercore ISI was out with optimistic coverage for the firm on May 4th as it raised the share price target to $236 from $232 and kept an Outperform rating on the stock. Earlier, Bank of America had bumped AbbVie Inc. (NYSE:ABBV)’s share price target to $234 from $226 and upgraded the rating to Buy from Neutral. The firm’s immunology business was part of BofA’s coverage, as the bank remarked that concerns about competitive pressures were excessive. The bank also discussed AbbVie Inc. (NYSE:ABBV)’s pipeline to remark that it had one of the best pipelines among large-cap peers. Cramer has discussed the company several times over the past couple of months. For instance, on April 30th, he remarked that AbbVie Inc. (NYSE:ABBV)’s immunology pipeline could be rivaled only by Eli Lilly. In this appearance, he defended the firm and mentioned the immunology portfolio again:

“The companies that have good stuff for autoimmune, like Abbvie, Abbvie is so cheap. Look at how cheap that is. And they had a great quarter. They crushed them.”

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.